Suggestions
Noah Berlow
Co-Founder & CTO (First Ascent Biomedical) | Techstars Boston 2021 | Assistant Member (cc-TDI)
I don't have enough specific information to provide details about Noah Berlow's role as an Adjunct Assistant Member at the Children's Cancer Therapy Development Institute (cc-TDI). However, I can share some general context about the organization he is affiliated with:
cc-TDI is a non-profit biotech laboratory focused on developing new treatments for childhood cancers.1 Their mission is to make childhood cancer universally survivable by translating scientific discoveries into clinical trials.12
The institute was founded in 2015 and has already pushed two drugs into three clinical trials for treating childhood cancers.1 This is significant progress, considering that only 10 drugs have been approved to treat childhood cancer since 1978, compared to an average of 12 drugs approved annually for adult cancers.1
cc-TDI's research team consists of biologists and engineers who work collaboratively with industry leaders worldwide.2 They aim to develop safe, effective, and less toxic drugs for underserved childhood cancers.2
As an Adjunct Assistant Member, Noah Berlow is likely involved in some capacity with cc-TDI's research efforts, though I don't have specific details about his particular role or contributions. The institute's work spans various areas including basic science and translational research, all conducted in their laboratory facility in Oregon.1
Highlights
Fantastic article by Kolawole Samuel Adebayo (KSA), featuring my First Ascent Biomedical co-founder Diana Azzam, PhD and our articles in Nature Medicine and the Conversation.
Personalization and AI are leading the fight to improve outcomes in cancer, even for stubborn and intractable cancers. Because the right drug for the right patient at the right time can make all the difference.
#PersonalizedMedicine #AI
Excited to share that I’ll be speaking on the Role of AI in Revolutionizing Biotech and Healthcare at the BioTech Day Summit in Franklin, TN on June 14th! I look forward to discussing the numerous ways the interface of AI and biotech will change paradigms and improve outcomes for patients, payers, and pharma.
For more details, visit: https://lnkd.in/eFyb9u5M #FirstAscent #AI #PersonalizedMedicine Diana Azzam, PhD Jim Foote First Ascent Biomedical
